Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches.
Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences.
Key Features
Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents
Reviews FDA-approved anti-angiogenesis agents
Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents
Offers insight into the development of novel anti-angiogenesis agents and future direction in this area
Readership
Pharmaceutical scientists and researchers in pharmaceutical and biotechnology companies, oncologists, hematologists, graduate and post-graduate students in these areas and academic faculty
Author(s): Shaker Mousa, Paul Davis (eds.)
Publisher: Academic Press
Year: 2016
Language: English
Pages: 210